논문검색
Author Dae Kyung Sohn, Seung Yong Jeong, Hyo Seong Choi, Seok Byung Lim, Jin Myeong Huh, Dae Hyun Kim, Dae Yong Kim, Young Hoon Kim, Hee Jin Chang, Kyung Hae Jung, Joong Bae Ahn, Hyun Kyung Kim, Jae Gahb Park
Place of duty Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Title Single Immunochemical Fecal Occult Blood Test for Detection of Colorectal Neoplasia
Publicationinfo Cancer Res Treat. 2005 Feb; 037(01): 20-23.
Key_word Fecal occult blood test,Screening,Colorectal neoplasm,Stage
Full-Text
Abstract Purpose: This study was designed to investigate the validity of a single immunochemical fecal occult blood test (FOBT) for detection of colorectal neoplasia. Materials and Methods: A total of 3,794 average-risk screenees and 304 colorectal cancer patients admitted to the National Cancer Center, Korea, between May 2001 and November 2002, were studied prospectively. All screenees and admitted patients underwent FOBT and total colonoscopic examinations. Stools were self-collected, and examined using an immunochemical fecal occult blood test (OC-hemodia , Eiken Chemical Co. Tokyo, Japan) and an OC-sensor analyzer (Eiken Chemical Co. Tokyo, Japan). Results: Of the 3,794 asymptomatic screenees, the colonoscopy identified colorectal adenomas and cancers in 613 (16.2%) and 12 (0.3%) subjects, respectively. The sensitivities of a single immunochemical FOBT for detec- ting colorectal cancers and adenomas in screenees were 25.0 and 2.4%, respectively. The false positive rate of FOBT for colorectal cancer in screenees was 1.19%. For the total 316 colorectal cancer cases (including 12 cases from screenees), the FOBT sensitivities according to the T-stage were 38.5, 75.0%, 78.9 and 79.2% for T1, 2, 3 and 4 cancers, respectively. The sensitivities according to the Dukes stages A, B and C were 63.4, 79.3 and 78.6%, respectively. Conclusion: The sensitivities of a single immunochemical FOBT for detecting colorectal cancers and adenomas in screenees were 25.0 and 2.4%, respectively. The sensitivities of FOBT were about 80% for Dukes B or C colorectal cancers and 63.4% for Dukes A. (Cancer Research and Treatment 2005;37:20-23)